Ehwest, ACTC.OB has submitted to the FDA for macular dystrophy and will be on track in the near future, possibly before GERN's well-publicized treament for spinal cord injury. Here is a 1 minute video and is why I spread my bets because these stem cell companies are all at different stages and any of them can be a target by big pharma or take the forefront in regenerative medicine.
Frankenstein will no longer be a fictious character. As far as ROSG they are not into stem cells. Don't know them, but along the same profile as them my favorite is SQNM that I invested in around 4 dollars that has had problems with handling data of their fetal DNA test which caused them to go back to the drawing board, but if they develop a prenatal Down's syndrome test without piercing the placenta it is worth billions, and their CEO (ex-Amgen CEO) said he is very encouraged and there "will be" a trisomy-21 test. HUGE upside there, but a major rollercoaster ride. No matter what, IP worth a few bucks a share (limited downside....huge upside). Good luck
News 
Market Data 
Discover 
